About: IS TEICOPLANIN A COMPLEMENTARY TREATMENT OPTION FOR COVID-19? THE QUESTION REMAINS

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: IS TEICOPLANIN A COMPLEMENTARY TREATMENT OPTION FOR COVID-19? THE QUESTION REMAINS Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	IS TEICOPLANIN A COMPLEMENTARY TREATMENT OPTION FOR COVID-19? THE QUESTION REMAINS
Creator	Alessandri, Francesco Ceccarelli, Giancarlo D'ettorre, Gabriella Mastroianni, Claudio Oliva, Alessandra Pugliese, Francesco Ruberto, Franco Venditti, Mario Borrazzo, Cristian Mario Venditti, Spagnolello, Ornella
source	Elsevier; Medline; PMC
abstract	covid:464fd896ae21975bf01610638e76d110c3459bf1#abstract
has issue date	2020-05-23(xsd:dateTime)
bibo:doi	10.1016/j.ijantimicag.2020.106029
bibo:pmid	32454071
has license	els-covid
sha1sum (hex)	464fd896ae21975bf01610638e76d110c3459bf1
schema:url	https://doi.org/10.1016/j.ijantimicag.2020.106029
resource representing a document's title	IS TEICOPLANIN A COMPLEMENTARY TREATMENT OPTION FOR COVID-19? THE QUESTION REMAINS
has PubMed Central identifier	PMC7245324
has PubMed identifier	32454071
schema:publication	Int J Antimicrob Agents
resource representing a document's body	covid:464fd896ae21975bf01610638e76d110c3459bf1#body_text
is schema:about of	named entity 'COVID' named entity 'TEICOPLANIN' named entity 'Staphylococcus aureus' named entity 'TDM' named entity 'FIPV' named entity 'antiviral agent' named entity 'CRP' named entity 'critical role' named entity 'pneumonia' named entity 'IC50' named entity 'Therapeutic drug monitoring' named entity 'bacterial infections' named entity 'SARS-CoV' named entity 'virus' named entity 'protein' named entity 'serum' named entity 'feline infectious peritonitis virus' named entity 'Ebola' named entity 'prognosis' named entity 'infection' named entity 'clearance rate' named entity 'influenza A and B viruses' named entity 'follow-up' named entity 'cathepsin' named entity 'ICU' named entity 'cathepsin' named entity 'ICU' named entity 'conformation' named entity 'procalcitonin' named entity 'lymphocyte count' named entity 'liver function' named entity 'ICU' named entity 'virus entry' named entity 'mechanical ventilation' named entity 'TDM' named entity 'respiratory viral infections' named entity 'teicoplanin' named entity 'superinfection' named entity 'cytoplasm' named entity 'receptor binding' named entity 'virus' named entity 'SARS-CoV-2' named entity 'virus' named entity 'loading dose' named entity 'kidney' named entity 'teicoplanin' named entity 'statistically significant' named entity 'SARS-CoV2' named entity 'teicoplanin' named entity 'cathepsin' named entity 'teicoplanin' named entity 'chemical derivatives' named entity 'teicoplanin' named entity 'lung' named entity 'MERS-CoV' named entity 'infection' named entity 'COVID' named entity 'Teicoplanin' named entity 'viruses' named entity 'virus' named entity 'SARS-CoV2' named entity 'SARS-CoV2' named entity 'serum' named entity 'treatment of patients' named entity 'TEICOPLANIN' named entity 'FOR' named entity 'COVID-19' named entity 'TREATMENT OPTION' named entity 'REMAINS' named entity 'COVID-19' named entity 'QUESTION'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software